G1 Therapeutics (NASDAQ:GTHX) Rating Increased to Hold at BidaskClub
G1 Therapeutics (NASDAQ:GTHX) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Wednesday, January 3rd.
Several other analysts have also issued reports on the stock. Cowen restated a “buy” rating on shares of G1 Therapeutics in a research report on Wednesday, November 8th. Zacks Investment Research downgraded shares of G1 Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Finally, BTIG Research started coverage on shares of G1 Therapeutics in a report on Tuesday, December 19th. They set a “buy” rating and a $38.00 price target on the stock. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $31.40.
Shares of G1 Therapeutics (GTHX) traded down $0.32 during mid-day trading on Wednesday, hitting $25.16. 15,260 shares of the stock were exchanged, compared to its average volume of 78,814. G1 Therapeutics has a 52-week low of $12.04 and a 52-week high of $28.67.
In related news, Director Fredric N. Eshelman bought 250,000 shares of the stock in a transaction dated Monday, November 13th. The shares were purchased at an average price of $19.73 per share, with a total value of $4,932,500.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Rajesh Malik sold 3,776 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $22.96, for a total transaction of $86,696.96. The disclosure for this sale can be found here. Insiders sold 545,932 shares of company stock worth $10,848,385 in the last three months.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Alps Advisors Inc. grew its holdings in shares of G1 Therapeutics by 9.1% in the third quarter. Alps Advisors Inc. now owns 27,766 shares of the company’s stock worth $691,000 after purchasing an additional 2,317 shares during the last quarter. Chartwell Investment Partners LLC grew its holdings in shares of G1 Therapeutics by 5.0% in the third quarter. Chartwell Investment Partners LLC now owns 92,558 shares of the company’s stock worth $2,303,000 after purchasing an additional 4,388 shares during the last quarter. American International Group Inc. bought a new position in shares of G1 Therapeutics in the third quarter worth about $130,000. California State Teachers Retirement System bought a new position in shares of G1 Therapeutics in the third quarter worth about $319,000. Finally, Schwab Charles Investment Management Inc. bought a new position in shares of G1 Therapeutics in the third quarter worth about $364,000. Hedge funds and other institutional investors own 43.25% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This report was reported by Marea Informative and is the sole property of of Marea Informative. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.mareainformativa.com/2018/01/30/g1-therapeutics-gthx-upgraded-to-hold-by-bidaskclub-updated-updated-updated.html.
About G1 Therapeutics
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.